Efficacy of interferential current transcutaneous electrical sensory stimulation through the neck skin for treating dysphagia in children with disabilities: A case series

Finding a suitable treatment for dysphagia has been challenging and the efficacy of neuromuscular electrical stimulation has been recognized. Moreover, the beneficial effect of interferential current transcutaneous electrical sensory stimulation has recently been described. However, the efficacy of interferential current transcutaneous electrical sensory stimulation in children with disabilities is unknown. Therefore, the aim of this study was to confirm the efficacy of interferential current transcutaneous electrical sensory stimulation in children with disabilities. Four children with disabilities of various types underwent interferential current transcutaneous electrical sensory stimulation once a week. All patients showed improved symptoms after interferential current transcutaneous electrical sensory stimulation treatment. Videoendoscopic examination showed reduced accumulation of secretion in all patients and decreased residual bolus in two. We also felt an increased forcefulness when swallowing in two. In addition, the questionnaire results regarding dysphagia indicated improvements. No significant side effects were observed. The interferential current transcutaneous electrical sensory stimulation treatment may be effective and safe in children with disabilities. The effect of this treatment on swallowing ability needs to be further investigated by studying more cases

sj-docx-1-sco-10.1177_2050313X221149527 – Supplemental material for Efficacy of interferential current transcutaneous electrical sensory stimulation through the neck skin for treating dysphagia in children with disabilities: A case series

Supplemental material, sj-docx-1-sco-10.1177_2050313X221149527 for Efficacy of interferential current transcutaneous electrical sensory stimulation through the neck skin for treating dysphagia in children with disabilities: A case series by Michinori Funato, Kanako Maruta, Mitsuru Yano, Mitsue Kai, Yaeko Umezawa, Kunihiko Yasuda, Emi Ohta-Noda and Keika Gen in SAGE Open Medical Case Reports</p

Varp Is a Novel Rab32/38-binding Protein That Regulates Tyrp1 Trafficking in Melanocytes

Two small GTPase Rabs, Rab32 and Rab38, have recently been proposed to regulate trafficking of melanogenic enzymes to melanosomes in mammalian epidermal melanocytes; however, the exact molecular mechanism of Rab32/38-mediated transport of melanogenic enzymes has never been clarified, because no Rab32/38-specific effector has ever been identified. In this study, we screened for a Rab32/38-specific effector by a yeast two-hybrid assay using a guanosine triphosphate (GTP)-locked Rab32/38 as bait and found that VPS9-ankyrin-repeat protein (Varp)/Ankrd27, characterized previously as a guanine nucleotide exchange factor (GEF) for Rab21, functions as a specific Rab32/38-binding protein in mouse melanocyte cell line melan-a. Deletion analysis showed that the first ankyrin-repeat (ANKR1) domain functions as a GTP-dependent Rab32/38-binding domain, but that the N-terminal VPS9 domain (i.e., Rab21-GEF domain) does not. Small interfering RNA-mediated knockdown of endogenous Varp in melan-a cells caused a dramatic reduction in Tyrp1 (tyrosinase-related protein 1) signals from melanosomes but did not cause any reduction in Pmel17 signals. Furthermore, expression of the ANKR1 domain in melan-a cells also caused a dramatic reduction of Tyrp1 signals, whereas the VPS9 domain had no effect. Based on these findings, we propose that Varp functions as the Rab32/38 effector that controls trafficking of Tyrp1 in melanocytes